详情

当前位置：首页> 国外交通科技报告数据库 >详情

原文传递 Novel Association and Therapeutic Targeting of Neuropilin-1 and MUC1 in Pancreatic Cancer. Final Technical Report September 30, 2012-September 29, 2015.

题名：	Novel Association and Therapeutic Targeting of Neuropilin-1 and MUC1 in Pancreatic Cancer. Final Technical Report September 30, 2012-September 29, 2015.
作者：	Bays, M. J.; Wettergren, T. A.
关键词：	Mine countermeasures, Unmanned surface vehicles, Unmanned underwater vehicles, Planning, Naval operations, Linear programming, Integer programming, Scheduling
摘要：	We hypothesized that MUC1, a transmembrane glycoprotein that is overexpressed in 80% of pancreatic ductal adenocarcinoma (PDA) induces a pro-angiogenic tumor microenvironment by increasing the level of NRP1 and VEGF there by enhancing angiogenesis and metastasis. We report that MUC1hi PC cells and tumors in vitro and in vivo not only express higher levels of NRP1 but also express higher levels of VEGFR2 and its phosphorylation forms as well as secrete higher levels of VEGF than MUC1 low PC cells. This enables the MUC1hi/NRP1hi cells to induce endothelial cell tube formation and generate long ectopic blood vessels and enhanced distant metastasis. In the proposal, we also hypothesized that blocking the interaction between VEGF165 and NRP1 within the tumor microenvironment will lead to therapeutic benefit. Indeed, in vivo blocking NRP1 significantly reduces tumor burden in the MUC1hi mouse and human tumors. For the in vivo MUC1-specific tumor targeting, we demonstrate that the antibody TAB004 binds MUC1+ve tumors in vitro and in vivo by Immunohistochemistry of primary human PDA tissues and by live animal imaging. Thus, NRP1 is a promising target for MUC11hi PDA. We conjugated TAB 004 to the a specific NRP-inhibitor for in vivo targeted therapy and show higher efficacy ofthe conjugate as compared to TAB004 alone or NRP-inhibitor alone in reducing VEGF secretion
报告类型：	科技报告